A Multicountry, Multicentre, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after First Line Osimertinib in patients with advanced and Metastatic NSCLC EGFRm in the GCC Region - TREASURE

Study identifier:D5161R00045

ClinicalTrials.gov identifier:NCT06039683

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Multicountry, Multicentre, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after First Line Osimertinib in patients with advanced and Metastatic NSCLC EGFRm in the GCC Region

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

266

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 31 Dec 2022
Estimated Primary Completion Date: 30 Jun 2024
Estimated Study Completion Date: 30 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria